Idylla EGFR Mutation Test

51 EGFR mutations in exons 18, 19, 20 and 21

~150 minutes assay turnaround time

< 2 minutes hands-on time

Only 1 slice of FFPE tissue required

Highly sensitive & standardized

Suitable for any lab

Idylla EGFR Mutation Test (CE-IVD)

Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla^TM EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge using only 1 FFPE tissue section from metastatic NSCLC showing a high concordance of >95% compared with reference methods.

Download technical sheet

Request demo

Catalog number: A0060/6

The Idylla™ EGFR Mutation Test contains PlexZyme and PlexPrime. More

Specimen requirements

One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla^TMSystem only a minimal amount of sample is needed

1x 5 μm FFPE tissue section
Neoplastic cells ≥10% - if less, macrodissection is required

IDYLLA™ FIRST

Guiding First-Line Therapy Decisions in NSCLC

Idylla First Lung Leaflet

Contribution of the Idylla System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

Petiteau et al. - Current Oncology. - November 2021

A prospective study demonstrating that the Idylla™ EGFR Mutation Test shortens time to patient management decisions for patients with NSCLC through the faster screening of EGFR mutations. With Idylla™, the timeframe from tumor sampling to the initiation of treatment was 16.1 calendar days earlier compared to NGS.

Do you want your biomarker results sooner?

The Idylla^TM System is a revolutionary, fully automated, molecular testing system designed to offer results in only 3 hours, shortening the time from sample to treatment initiation to 1 or 2 days.

Meet Idylla Request demo

Testimonial

Today, EGFR testing is a cumbersome process and it often takes several weeks before results are analyzed. This may lead to the administration of anti-EGFR therapy as second-line agents, which is less efficient than their use in first-line therapy. The Idylla^TM EGFR Mutation assay technology has the potential to change that; it is a cost-effective solution, ensuring reliable and fast detection of all relevant mutations.

Prof Giancarlo Troncone
University of Napoli Federico II, Naples, Italy

Idylla Oncology Assays

Back to overview